CLINICAL EVALUATION OF JB-329 (DITRAN).
D000987:Antisocial Personality Disorder; D001714:Bipolar Disorder; D003863:Depression; D004338:Drug Combinations; D006016:Glycolates; D006213:Hallucinogens; D001523:Mental Disorders; D010880:Piperidines; D011618:Psychotic Disorders; D011759:Pyrrolidines; D012559:Schizophrenia; D014116:Toxicology
D004338:Drug Combinations; D006016:Glycolates; D006213:Hallucinogens; D010880:Piperidines; D011759:Pyrrolidines; C001621:1-ethyl-2-pyrrolidinylmethyl-alpha-phenylcyclopentylglycolate, 1-ethyl-3-piperidyl-alpha-phenylcyclopentylglycolate drug combination
DEPRESSION; HALLUCINOGENS; PSYCHOSES, MANIC-DEPRESSIVE; SCHIZOPHRENIA; SOCIOPATHIC PERSONALITY; TOXICOLOGIC REPORT